UNSPSC 51101614: Diloxanide furoate

This classification denotes an antiparasitic agent with the molecular formula C9H9Cl2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 89134SCM7M, chemically known as 2,2-dichloro-4-hydroxy-n-methylacetanilide but generally known as diloxanide, which bears US NIH Compound Identifier 11367. European Medicines Agency schedules Diloxanide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07147MIG.

UNSPSC 51101614 Diloxanide furoate is a Commodity code for a specific antiprotozoal pharmaceutical product, but recent state and local opportunities tagged under this code show little activity aligned with its nominal scope. The Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026, though the award covered Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets—antibiotics unrelated to diloxanide furoate. Seminole County, Florida released an IFB in June 2026 for Naloxone and Safe Drug Deactivation Systems, annual quantities of 1,900 units and 800 units respectively with quarterly deliveries to the county's Community Health Building in Sanford—a public-health procurement bearing no connection to the antiprotozoal product the code nominally describes. State and local governments use UNSPSC codes inconsistently; the tagging mismatch here suggests either miscoding in the source data or category drift over time. Decision-relevant activity under the code's true commodity scope does not appear in the recent opportunities block.

The geographic spread of tagged activity spans Illinois and Florida, though neither opportunity involves diloxanide furoate procurement. The Illinois award to a state department through a consortium vehicle and the Seminole County IFB through county e-procurement represent typical state and local procurement channels, but neither signals demand for the pharmaceutical product this code nominally covers. Firms evaluating pursuit under this code should verify category alignment with prospective customers and expect that posted opportunities may not match the code's intended commodity scope.